iRhythm Technologies Beheer

Beheer criteriumcontroles 2/4

De CEO iRhythm Technologies is Quentin Blackford, benoemd in Oct2021, heeft een ambtstermijn van 3.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 16.60M, bestaande uit 4.1% salaris en 95.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.26% van de aandelen van het bedrijf, ter waarde € 6.26M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 7.3 jaar.

Belangrijke informatie

Quentin Blackford

Algemeen directeur

US$16.6m

Totale compensatie

Percentage CEO-salaris	4.1%
Dienstverband CEO	3.1yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	7.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Quentin Blackford's beloning veranderd ten opzichte van iRhythm Technologies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$151m
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$130m
Dec 31 2023	US$17m	US$677k	-US$123m
Sep 30 2023	n/a	n/a	-US$105m
Jun 30 2023	n/a	n/a	-US$99m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$8m	US$650k	-US$116m
Sep 30 2022	n/a	n/a	-US$128m
Jun 30 2022	n/a	n/a	-US$131m
Mar 31 2022	n/a	n/a	-US$124m
Dec 31 2021	US$10m	US$163k	-US$101m

Compensatie versus markt: De totale vergoeding ($USD 16.60M ) Quentin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.95M ).

Compensatie versus inkomsten: De vergoeding van Quentin is gestegen terwijl het bedrijf verliesgevend is.

CEO

Quentin Blackford (45 yo)

3.1yrs

Tenure

US$16,595,149

Compensatie

Mr. Quentin S. Blackford serves as an Independent Director of Paragon 28, Inc. since August 1, 2022. He serves as President and Chief Executive Officer since October 04, 2021 and serves as Director at iRhy...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Quentin Blackford	President	3.1yrs	US$16.60m	0.26% € 6.3m
Minang Turakhia	Chief Medical & Scientific Officer and Executive VP of Product Innovation	2.6yrs	US$5.32m	0.015% € 370.5k
Patrick Murphy	Chief Business & Legal Officer	2.9yrs	US$5.33m	0.031% € 730.0k
Chad Patterson	Chief Commercial Officer	2.3yrs	US$5.77m	0.025% € 600.8k
Mervin Smith	Executive Vice President of Business Operations	1.3yrs	geen gegevens	0.0023% € 56.0k
Marc Rosenbaum	Senior VP of Finance & Chief Accounting Officer	1.3yrs	geen gegevens	0.0029% € 69.4k
Daniel Wilson	Executive VP of Corporate Development & Investor Relations	5.4yrs	US$3.54m	0.098% € 2.3m
Sumi Shrishrimal	Executive VP & Chief Risk Officer	2.5yrs	geen gegevens	0.074% € 1.8m
Stephanie Zhadkevich	Director of Investor Relations	no data	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

45yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van I25 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Quentin Blackford	President	2.8yrs	US$16.60m	0.26% € 6.3m
Ralph Snyderman	Independent Director	7.3yrs	US$233.12k	0.032% € 771.1k
Michael Mirro	Medical Director & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Bruce Bodaken	Independent Director	7.3yrs	US$240.25k	0.030% € 721.4k
Abhijit Talwalkar	Independent Chairman	8.5yrs	US$286.74k	0.055% € 1.3m
R. Mead	Medical Director & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
James Quinn	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Cathleen Noel Merz	Independent Director	6.6yrs	US$230.62k	0.018% € 441.3k
Mark Rubash	Independent Director	8.7yrs	US$248.12k	0.034% € 809.1k
Mehdi Razavi	Medical Director & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Karen Ling	Independent Director	3yrs	US$239.97k	0.020% € 486.7k
Jay Alexander	Medical Director & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

7.3yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van I25 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).

iRhythm Technologies Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

President recently sold €1.1m worth of stock

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

President recently sold €2.8m worth of stock

Insider recently sold €680k worth of stock

Executive VP & Chief Risk Officer recently sold €115k worth of stock

iRhythm Technologies, Inc. Announces Director Appointments

Recent updates

President recently sold €1.1m worth of stock

Third quarter 2024 earnings released: US$1.48 loss per share (vs US$0.89 loss in 3Q 2023)

iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device

iRhythm Technologies, Inc. to Report Q3, 2024 Results on Oct 30, 2024

New minor risk - Profitability

iRhythm Technologies, Inc. Reaffirms Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. Announces Results of GUARD-AF Trial

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.65 loss per share (vs US$0.61 loss in 2Q 2023)

Irhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q2, 2024 Results on Aug 01, 2024

iRhythm Technologies, Inc. Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation

Forecast to breakeven in 2026

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q1, 2024 Results on May 02, 2024

New minor risk - Profitability

iRhythm Technologies, Inc., Annual General Meeting, May 29, 2024

New minor risk - Shareholder dilution

President recently sold €2.8m worth of stock

Forecast to breakeven in 2026

Full year 2023 earnings released: US$4.04 loss per share (vs US$3.88 loss in FY 2022)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2024

iRhythm Technologies, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against iRhythm Technologies, Inc

iRhythm Technologies, Inc. Revises Revenue Guidance for the Year 2024

Insider recently sold €680k worth of stock

iRhythm , Inc. Announces Results from the Cardiac Ambulatory Monitor EvaLuation of Outcomes and Time to Events

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.89 loss per share (vs US$0.71 loss in 3Q 2022)

iRhythm Technologies, Inc. to Report Q3, 2023 Results on Nov 02, 2023

iRhythm Launches Next Generation Zio Monitor and Enhanced Zio Service: Its Smallest, Lightest and Thinnest Cardiac Monitor

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$0.80 loss in 2Q 2022)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Full Year 2023

iRhythm Technologies, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Executive VP & Chief Risk Officer recently sold €115k worth of stock

iRhythm Technologies, Inc. Announces Director Appointments

iRhythm Technologies, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$1.29 loss per share (vs US$1.71 loss in 1Q 2022)

Now 23% undervalued

COO & Secretary recently sold €391k worth of stock

Full year 2022 earnings released: US$3.88 loss per share (vs US$3.46 loss in FY 2021)

iRhythm Technologies, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Chief Legal Counsel recently sold €174k worth of stock

President recently sold €1.6m worth of stock

Now 20% undervalued after recent price drop

Third quarter 2022 earnings released: US$0.71 loss per share (vs US$0.81 loss in 3Q 2021)

iRhythm Technologies, Inc. Revises Earnings Guidance for the Year 2022

iRhythm Technologies, Inc. to Report Q3, 2022 Results on Nov 01, 2022

iRhythm Technologies, Inc. Reiterates Revenue Guidance for the Year 2022

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year of 2022

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.59 loss in 2Q 2021)

iRhythm Technologies, Inc. Appoints Brice Bobzien as Chief Financial Officer, Effective August 8, 2022

iRhythm Gains FDA Clearance for its Clinically Integrated ZEUS System

iRhythm Technologies, Inc. Announces Management Changes

Executive Vice President of Strategy recently sold €152k worth of stock

Independent Director recently sold €54k worth of stock

First quarter 2022 earnings released: US$1.71 loss per share (vs US$0.95 loss in 1Q 2021)

iRhythm Technologies, Inc. Provides Earnings Guidance for the Fiscal Year 2022

iRhythm Technologies, Inc. to Report Q1, 2022 Results on May 05, 2022

iRhythm Technologies, Inc., Annual General Meeting, May 26, 2022

iRhythm Technologies, Inc. Announces the Results of Three Clinical Research Studies Presented At the American College of Cardiology’s 71 Annual Scientific Session & Expo

Consultant & Director recently sold €828k worth of stock

iRhythm Technologies, Inc. Announces the Results of the KP-Rhythm2 Study

iRhythm Technologies, Inc. Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

COO, CFO & Secretary recently sold €490k worth of stock

iRhythm Technologies, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Insufficient new directors

Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.17 loss in 3Q 2020)